Newly proposed candidate Zika virus vaccines might or might not succeed in raising safe, effective, and durable protection against human Zika virus infections or syndromes. Analyses of a clinically tested and licensed dengue vaccine that failed to protect seronegative individuals from breakthrough or enhanced dengue infections suggest that poor T-cell immunity might have contributed to protection failure. Because of the similarity of Zika and dengue viruses, an analogous unwanted outcome might occur with some Zika virus vaccine designs. A successful Zika virus vaccine requires challenge experiments that are done at long intervals after immunisation and that identify protection as the absence of viraemia and the absence of an anamnestic antibody response. T-cell immunity might be an essential component of safe, efficacious, and durable Zika virus vaccines.

新近提出的候选寨卡病毒疫苗可能或不能成功提高针对人类寨卡病毒感染或综合症的安全，有效和持久的保护能力。对经过临床测试和许可的登革热疫苗的分析未能保护血清阴性个体免受突破性登革热或增强型登革热感染的影响，这表明不良的T细胞免疫力可能导致了保护失败。由于寨卡病毒和登革热病毒的相似性，某些寨卡病毒疫苗设计可能会产生类似的不良后果。成功的寨卡病毒疫苗需要进行挑战性实验，这些实验需在免疫后长间隔进行，并将保护性识别为无病毒血症和无记忆抗体应答。T细胞免疫力可能是安全，有效，